글로벌 전신 항생제 시장 – 2029년까지의 산업 동향 및 예측

전신 항생제 시장 분석 및 규모

글로벌 전신 항생제 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 전신 항생제 시장의 성장은 다양한 감염성 질환의 증가와 많은 제약 회사에서 수행하는 연구 개발 활동의 출시로 가속화됩니다. 신약 개발을 위한 R&D 투자 증가로 예측 기간 동안 글로벌 전신 항생제 시장이 증가할 것으로 예상됩니다. 절개 및 배액 후 피부 및 연조직 농양에 대한 전신 항생제의 광범위한 사용으로 임상적 치료율이 높아졌습니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 전신 항생제 시장의 성장률을 분석합니다. 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함됩니다.

시장 정의

항생제는 생명을 위협하는 질환과 감염을 치료하는 데 사용되는 필수적인 약물입니다. 전신 항생제는 박테리아 감염을 치료하는 데 사용되는 항생제의 일종으로, 경구 또는 정맥으로 투여됩니다. 이러한 항생제는 신체 전체에 작용하여 감염을 제거하는 데 도움이 됩니다. 아목시실린, 마크로라이드, 테트라사이클린, 세팔로스포린 및 메트로니다졸은 치주 및 치근관 질환을 포함한 치과 질환을 치료하는 데 사용되는 주요 전신 항생제입니다.

전신 항생제 시장 범위 및 세분화

Global Systemic Antibiotics Market Dynamics

Drivers

• Increased Incidence of Cancer and Infectious Diseases

Increasing cancer and other infectious diseases are expected to boost the market growth over the forecast period 2022-2029. For instance, as per the CDC reports U.S, 1,752,735 new cancer cases along with 599,589 deaths were reported in 2019. Further, according to Globocan 2020, U.K., 457,960 new cases with 179,648 deaths were reported in 2020. According to the reports, the most common types of malignancies witnessed were breast, prostate cancer and Non-Hodgkin’s lymphoma. Thus, this boosts the market growth.

• Rise in Prevalence of Chronic Diseases

Periodontal diseases, tooth loss and decay are pervasive dental disorders worldwide. For instance, it is projected that periodontal disease is extremely prevalent in the elderly population and affects 20% to 50% of the population worldwide. Furthermore, diabetic mellitus leading to diabetic foot infections, urinary tract infections, and other contagious diseases is rising across the globe. This is anticipated to boost the demand for systemic antibiotics in the upcoming years. Rise in skin infections and other chronic wounds is expected to increase demand for systemic antibiotics during the forecast period.

Opportunities

• Higher Investments in Research Activities

A rise in research and new drug development investment is projected to boost the global systemic antibiotics market during the forecast period. For instance, the U.S. invested US$ 260 Mn and US$ 410 Mn in antibiotic R&D activities in 2015 and 2016, respectively. Thus, this type of healthcare expenditure is expected to create opportunities for the market growth.

• Increasing Initiatives from Government

Several launch and implementation of numerous government initiatives such as antibiotic stewardship by CDC for the promotion of the appropriate use of antibiotics and reduction of antimicrobial resistance is expected to enlarge the global systemic antibiotics market during the forecast period.

 Restraints/Challenges

• Adverse Complications of Antibiotics

The occurrence of antibiotic resistance by numerous species of bacteria and adverse reactions including allergic reactions, anaphylaxis, hypersensitivity reactions, and rashes associated with intake of systemic antibiotics, are projected to restrict the global market growth in the near future. For instance, tinnitus, pigment deposition of skin, pharyngitis, dizziness, gastrointestinal disturbances, photosensitivity caused due to tetracycline, C. difficile infection, and macrolides during acne treatment are expected to impede the growth of the global systemic antibiotics market in the next few years.

• High Cost

The huge expenditure associated with the type of systemic antibiotics such as Beta Lactam & Beta Lactamase Inhibitors, Quinolone hamper the market growth.

This global systemic antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global systemic antibiotics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Systemic Antibiotics Market            

COVID-19 has left an unparalleled global public health crisis that has impacted practically every business. Its long-term consequences are expected to effect industry growth during the forecast period. Shift of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. During the pandemic, healthcare organizations avoided non-urgent medical needs. Major market players witnessed a decline in their revenue.

In the post-pandemic era, changes are witnessed as increase in the use of systemic antibiotics were on the rise. The socioeconomic stressors have also boosted the demand for these drugs. Thus, this will leave a significant impact on the narcotic drugs market.

Global Systemic Antibiotics Market Scope

The global systemic antibiotics market is segmented on the basis of indication, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Beta Lactam & Beta Lactamase Inhibitors
• Clavulanic acid
• Sulbactam
• Tazobactam
• Quinolone
• Moxifloxacin
• Ciprofloxacin
• Macrolide
• Erythromycin
• Clarithromycin
• Others

Indication

• Urinary Tract Infection
• Intra-Abdominal Infections
• Blood Stream Infections
• Clostridium Difficile Infections
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Systemic Antibiotics Market Regional Analysis/Insights

The global systemic antibiotics market is analysed and market size insights and trends are provided by indication, drug class, distribution channel and end-user as referenced above.

The major countries covered in the global systemic antibiotics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for narcotic drugs market throughout the forecasted period due to the high prevalence of infectious diseases, sophisticated medical facilities and rise in government initiatives.

Asia-Pacific dominates the market due to the key generic players and increases focuses on the research and development activity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Systemic Antibiotics Market Share Analysis

글로벌 전신 항생제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 전신 항생제 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 전신 항생제 시장에서 활동하는 주요 기업은 다음과 같습니다.

• ANI Pharmaceuticals, Inc. (미국)
• Fresenius SE & Co. KGaA(독일)
• 파이저 주식회사(미국)
• 마일런 NV(미국)
• Novartis AG(스위스)
• Hikma Pharmaceuticals plc (영국)
• Aurobindo Pharma(인도)
• Abbvie, Inc(미국)
• 멜린타 테라퓨틱스 주식회사(미국)
• Janssen Global Services, LLC(미국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• GSK plc. (영국)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Glenmark Pharmaceuticals Ltd(인도)

SKU-54342